Laromustine

N/A

Report date: 2022/11/25 16:34:12
NME

Base Information

Drug NameLaromustine
Drug Alias Namelaromustinum拉罗莫司汀laromustine拉莫司汀laromustina +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNanotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViron Therapeutics IncNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[6] 
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[10] 

Other Information

ATC CodeN/A
Related LinksKEGG